Since the anti-melanoma response of HD IL-2 differs between genetic subsets of advanced melanoma [31], these HD IL-2-based combination therapies described above might be improved by comprehensive analysis for the driver genes of melanoma before the administration of therapy. Here, IL2 is linked to melanoma.